Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000176790 | SCV000228511 | uncertain significance | not provided | 2014-06-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002345606 | SCV002648789 | uncertain significance | Cardiovascular phenotype | 2019-02-21 | criteria provided, single submitter | clinical testing | The p.R18498C variant (also known as c.55492C>T), located in coding exon 153 of the TTN gene, results from a C to T substitution at nucleotide position 55492. The arginine at codon 18498 is replaced by cysteine, an amino acid with highly dissimilar properties. This variant was reported (as NM_001267550.1:c.82687C>T p.R27564C) in an individual with dilated cardiomyopathy (DCM); however, the individual also had an additional TTN variant and clinical details were limited (Begay RL et al. J Am Heart Assoc, 2015 Nov;4:[Epub ahead of print]). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002492764 | SCV002778756 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J; Tibial muscular dystrophy; Myopathy, myofibrillar, 9, with early respiratory failure; Early-onset myopathy with fatal cardiomyopathy; Hypertrophic cardiomyopathy 9 | 2021-10-19 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000176790 | SCV003824932 | uncertain significance | not provided | 2019-11-25 | criteria provided, single submitter | clinical testing |